Gentian Diagnostics AS (OSL:GENT) Total Liabilities: kr50.3 Mil (As of Mar. 2026)

What is Gentian Diagnostics AS Total Liabilities?

Gentian Diagnostics AS OSL:GENT -4.88% 73 Total Liabilities is kr50.3 Mil as of Mar. 2026. GuruFocus rates OSL:GENT with a GF Score™ of 73/100 and a GF Value™ of kr61.88 (Possible Value Trap). The stock has 1 warning sign investors should review.

Gentian Diagnostics AS's Total Liabilities for the quarter that ended in Mar. 2026 was kr50.3 Mil.

Gentian Diagnostics AS's quarterly Total Liabilities increased from Sep. 2025 (kr30.66 Mil) to Dec. 2025 (kr53.58 Mil) but then declined from Dec. 2025 (kr53.58 Mil) to Mar. 2026 (kr50.29 Mil).

Gentian Diagnostics AS's annual Total Liabilities increased from Dec. 2023 (kr34.40 Mil) to Dec. 2024 (kr35.61 Mil) and increased from Dec. 2024 (kr35.61 Mil) to Dec. 2025 (kr53.58 Mil).

Gentian Diagnostics AS Total Liabilities Related Terms

Gentian Diagnostics AS Total Liabilities Historical Data

* Premium members only.

The historical data trend for Gentian Diagnostics AS's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gentian Diagnostics AS Total Liabilities Chart

Gentian Diagnostics AS Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

37.02

33.62

34.40

35.61

53.58

Gentian Diagnostics AS Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Liabilities	Get a 7-Day Free Trial															32.44	33.75	30.66	53.58	50.29

73GF Score

Gentian Diagnostics AS OSL:GENT

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Gentian Diagnostics AS Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Gentian Diagnostics AS's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	34.14	+	(19.442	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	53.6

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	258.539	-	204.957
	=	53.6

Gentian Diagnostics AS's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	32.583	+	(17.705	+	0.0010000000000048
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	50.3

Total Liabilities	=	Total Assets (Q: Mar. 2026 )	-	Total Equity (Q: Mar. 2026 )
	=	235.497	-	185.208
	=	50.3

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of kr50.3 Mil mean?

Gentian Diagnostics AS (OSL:GENT) has a Total Liabilities of kr50.3 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Gentian Diagnostics AS and its competitors.

Is Gentian Diagnostics AS's Total Liabilities too high?

Gentian Diagnostics AS's current Total Liabilities is kr50.3 Mil. Overall, Gentian Diagnostics AS has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Gentian Diagnostics AS's Total Liabilities compare to ABT and SYK?

Gentian Diagnostics AS's Total Liabilities of kr50.3 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Medical Devices & Instruments company?

A good Total Liabilities depends on the Medical Devices & Instruments industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Gentian Diagnostics AS and its competitors. Gentian Diagnostics AS's current Total Liabilities is kr50.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Gentian Diagnostics AS stock overvalued right now?

Based on GuruFocus' analysis, Gentian Diagnostics AS (OSL:GENT) is currently considered Possible Value Trap. The stock's GF Value™ is kr61.88, compared to a current price of kr37.00 — trading 40.2% below its estimated fair value. The current Total Liabilities is kr50.3 Mil. Gentian Diagnostics AS's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For Gentian Diagnostics AS (OSL:GENT), the current Total Liabilities is kr50.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gentian Diagnostics AS (OSL:GENT) Overvalued in 2026?

Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued. The current stock price of kr37.00 is trading 40.2% below its estimated GF Value™ of kr61.88. GuruFocus considers Gentian Diagnostics AS to be Possible Value Trap.

Key valuation signals for OSL:GENT:

Total Liabilities: kr50.3 Mil
GF Value™: kr61.88 vs. price of kr37.00 (40.2% below fair value)
GF Score™: 73/100 with 1 warning sign

No single metric tells the full story. See the OSL:GENT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gentian Diagnostics AS Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies OSL:OBSRV OSL:LIFE ABT SYK MDT BSX EW XTER:SHL GEHC DXCM XAMS:PHIA SZSE:300760 STE ZBH XSWX:SOON LSE:SN.PEN SHSE:688271 GMED TSE:7733

Other Exchanges GENTOo:Sweden 6FK:Germany

Address Bjornasveien 5, Moss, NOR, 1596

Website https://www.gentian.com

Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.

73GF Score

Get the complete analysis for OSL:GENT

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr37.00

Price

kr61.88

GF Value

View OSL:GENT Analysis

See Total Liabilities data for all stocks →